C12Y 304/24035
Gelatinase b , i.e. matrix metalloprotease 9 or mmp9
Official title: Gelatinase B (3.4.24.35), i.e. matrix metalloprotease 9 or MMP9
C12Y304/24035 (Gelatinase b , i.e. matrix metalloprotease 9 or mmp9) appears on 26 US grants and 56 published applications in this corpus.
Search patents in C12Y- Granted patents
- 26
- Published applications
- 56
- Assignees
- 46
- Inventors
- 127
- Latest grant
- 7 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2009 | 0 | 1 |
| 2010 | 0 | 0 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 4 |
| 2014 | 1 | 2 |
| 2015 | 2 | 6 |
| 2016 | 1 | 4 |
| 2017 | 3 | 4 |
| 2018 | 3 | 1 |
| 2019 | 1 | 6 |
| 2020 | 3 | 3 |
| 2021 | 2 | 3 |
| 2022 | 2 | 3 |
| 2023 | 4 | 7 |
| 2024 | 2 | 3 |
| 2025 | 0 | 3 |
| 2026 | 2 | 5 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Targeted chondroitinase ABC fusion proteins and complexes thereof7 Jul 2026US 12,674,155 B2University of Florida Research Foundation, Inc.
- Protease-cleavable substrates and methods of use thereof5 May 2026US 12,617,856 B2CytomX Therapeutics, Inc.
- Autophagy as a therapeutic target for intracranial aneurysm15 Oct 2024US 12,116,597 B2Board of Regents, The University of Texas System
- Oncolytic viral delivery of therapeutic polypeptides9 Jan 2024US 11,865,081 B2Virogin Biotech Canada Ltd
- IL-15 prodrugs and methods of use thereof19 Dec 2023US 11,845,801 B2AskGene Pharma Inc.
- Enhanced macrophages2 Apr 2026US 2026/0091058 A1Resolution Therapeutics Limited
- Therapeutic macrophages26 Mar 2026US 2026/0085287 A1Resolution Therapeutics Limited
- Protease-cleavable moieties and methods of use thereof19 Feb 2026US 2026/0049148 A1CytomX Therapeutics, Inc.
- Protease-cleavable moieties and methods of use thereof12 Feb 2026US 2026/0042849 A1CytomX Therapeutics, Inc.
- Co-transplantation of mmp-9 enhanced mesenchymal stem cells and pancreatic islets for the treatment of diabetes22 Jan 2026US 2026/0021169 A1University of Maryland, Baltimore
Most cited
By later US patents
- Aptamers inhibiting the enzymatic activity of the MMP-9 protein6US 9,902,961 B2Institut National De La Sante Et De La Recherche Medicale (Inserm) · 2018
- Method of detecting human matrix metalloproteinase 9 using antibodies5US 9,550,836 B2Gilead Biologics, Inc. · 2017
- Gelatinase inhibitors and prodrugs3US 8,937,151 B2University of Notre Dame du Lac · 2015
- Methods and compositions for treatment of traumatic brain injury and for modulation of migration of neurogenic cells3US 9,828,593 B2SanBio, Inc. · 2017
- Antibodies to matrix metalloproteinase 92US 10,800,857 B2Gilead Biologics, Inc. · 2020